Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology

R.D. Solorzano

April 27, 2025

Organovo Holdings, Inc. (Nasdaq: ONVO), a pioneer in 3D bioprinting technology, announced today that it will officially change its name to VivoSim Labs, Inc., marking a new chapter in the company’s mission to advance bioprinting innovations. The rebranding takes effect on April 24, 2025, when the company will begin trading under the new ticker symbol “VIVS” on the Nasdaq Capital Market.

The shift to VivoSim Labs reflects the company’s evolving focus and commitment to driving forward its legacy in 3D bioprinting. While the name and ticker symbol will change, the company’s common stock will continue to trade on the Nasdaq, and its CUSIP number (68620A302) remains unchanged. No action is required from current shareholders as part of this transition.

About Organovo

Founded in San Diego, Organovo has been recognized as an innovator in tissue engineering, utilizing 3D bioprinting to create functional human tissues for medical research and therapeutic applications. The rebranding to VivoSim Labs signals the company’s intent to broaden its platform capabilities, potentially expanding its reach into new areas of biomedical research.

Original article can be found here.

2 responses to “Organovo Rebrands as VivoSim Labs to Advance 3D Bioprinting Technology”

Charles G Tessler

May 8, 2025 at 9:17 am

Trying to understand why VIVS/Organovo hasn’t a higher rating by the pundits such as CFR who have advised holders to sell their position. After selling their FXR program and Patents Eli Lilly and being paid $50 mm at closing in March 2025 why would the new named but same fundamental company not be rated higher and at least grading at least a hold recommendation? Their product seems to still fully reflect a special business biomedical platform deserving better ratings after creating and selling the FXR platform. In addition do any of the original Organovo holders have any part of any Eli Lilly stock or stock equity in the purchasing entity?

Charles G Tessler, charlent1@comcast.net/cgt@jumpinjanet.com 5/8/2025

LikeLike

Reply
R.D. Solorzano

May 9, 2025 at 10:46 am

Hey Charles, many thanks for the comment. While we are not financial advisors, we can speculate, the recent Eli Lilly sale is a great first step for a company that has had a history of struggling to bring projected projects to fruition, from bioprinters, tissue models, to medical devices. Their strategy to develop sellable assets off of their models is a great direction not just for the company, but for the industry. From a financial perspective though, it remains to be seen if the $50M which are milestone payments not upfront payments can be achieved, and if further sellable assets can be delivered. I’ve seen a few ratings give a hold and believe that’s more in line with their position.

LikeLike

Reply

The Business of Biofabrication